Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a San Diego-based clinical-stage biotech company specializing in the development of safer prescription drugs using its proprietary technology platforms. The company focuses on creating new, tamper-proof opioids that aim to reduce drug abuse and prevent overdoses. Ensysce leverages its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms to develop innovative pain relief options with a lower risk of misuse.
The company’s core projects include two key drug platforms: the TAAP technology, which activates upon ingestion to release pain medication, and the MPAR technology, designed to prevent overdose by inhibiting further release of the drug when excess doses are consumed. These platforms are supported by global intellectual property protection, ensuring a wide array of prescription drug compositions.
Recent milestones include the FDA’s Breakthrough Therapy designation for PF614-MPAR, a combination product designed to provide overdose protection alongside effective pain relief. This designation accelerates the drug’s development and review process, highlighting its potential to offer substantial improvements over existing therapies. Ensysce’s lead candidate, PF614, is currently in Phase 3 clinical development, having demonstrated efficacy and safety in previous trials.
In terms of financial health, Ensysce has shown stability, with recent funding from federal grants and warrant exercises supporting ongoing research and development. The company's collaboration with Quotient Sciences aims to further optimize their PF614-MPAR drug product, enhancing its effectiveness and safety profile.
Ensysce is also expanding its product pipeline to address opioid use disorder (OUD) with PF9001, a TAAP-based candidate that has shown promise in reducing cardiovascular side effects compared to traditional treatments. Supported by a multi-year HEAL grant from the NIH and NIDA, this candidate is poised to enter human clinical studies within the next 12 to 18 months.
For more detailed information about Ensysce Biosciences, Inc. and its innovative projects, please visit www.ensysce.com.
Ensysce Biosciences, a clinical-stage biotech firm, reported Q3 2022 financials highlighting a net loss of $9.9 million, a decrease from $17.2 million year-over-year. Cash reserves stood at $4.5 million, up from $3.7 million in the previous quarter. The CEO noted positive topline results from the human abuse potential study of PF614, indicating its advantages over existing products. Furthermore, the FDA provided guidance supporting PF614's development for acute pain. R&D expenses surged to $4.8 million, reflecting ongoing clinical activities.
Ensysce Biosciences (NASDAQ:ENSC) announced receiving FDA guidance regarding its lead product, PF614, indicating that pursuing an acute pain indication is advisable. The FDA's non-binding guidance suggests conducting two clinical trials comparing PF614 with a placebo and an immediate-release opioid like oxycodone. This strategy may reduce the development timeline and costs, compared to a chronic pain focus. Ensysce plans to advance PF614 for acute pain while continuing chronic pain development, aiming to complete human abuse potential studies and initiate Phase 3 trials in the upcoming year.
Ensysce Biosciences has announced positive topline results from a human abuse potential (HAP) study of PF614, an innovative oxycodone product designed to deter abuse. The study demonstrated that PF614 resulted in significantly lower peak 'drug liking' compared to traditional oxycodone. This is crucial for its FDA approval process, aligning with the agency's guidance on evaluating abuse potential. The company is committed to advancing this product into Phase 3 studies, addressing a significant need for safer analgesics in chronic pain management.
Ensysce Biosciences (NASDAQ:ENSC) has initiated the PF614-104 study, focusing on the drug's abuse deterrent properties against oxycodone. The trial tests the oral abuse potential of PF614 in non-dependent recreational opioid users, comparing it to oxycodone and placebo. The study's primary outcome is 'Drug Liking,' essential for future commercialization and labeling. Ensysce's TAAP® technology ensures PF614 is inert without trypsin exposure, potentially reducing abuse risks. Preliminary data is expected in early 2023, marking a significant step towards safer opioid alternatives.
Ensysce Biosciences has initiated the PF614-104 trial, a study to evaluate the oral abuse potential of its drug PF614 compared to oxycodone. Conducted by Dr. Brad Vince, this randomized trial aims to demonstrate that PF614 has less drug liking potential, crucial for its abuse deterrent labeling. This follows the company's previous Human Abuse Potential study, reflecting significant progress in PF614's development. With PF614 exhibiting bioequivalence to OxyContin and a longer half-life for sustained pain relief, results are expected in early 2023.
Ensysce Biosciences (NASDAQ:ENSC) announced its participation in the Benzinga All Access investor event on September 23, 2022. Dr. Lynn Kirkpatrick, CEO, will present at 9:20 AM Eastern time, followed by a Q&A session. The event will be available via a live video webcast, with an archived replay on the Benzinga YouTube Channel. Ensysce focuses on developing tamper-proof prescription drugs to enhance drug safety and combat abuse and overdose risks, leveraging its TAAP™ and MPAR™ technologies.
Ensysce Biosciences held a special meeting of stockholders on September 8, 2022, where key resolutions were approved. Stockholders voted in favor of:
- Issuing shares of common stock to certain investors, ensuring compliance with Nasdaq Listing Rule 5635(d).
- Implementing a Reverse Stock Split at a ratio between one-for-five and one-for-twenty.
- Increasing the number of authorized shares of common stock.
The decisions aim to strengthen the company’s capital structure and support ongoing clinical development initiatives.
Ensysce Biosciences has launched a redesigned corporate website highlighting its innovative TAAP and MPAR technology platforms aimed at improving prescription drug safety. The website aims to enhance communication about its unique, tamper-proof pain treatment options and the company's mission to combat drug abuse and overdoses. CEO Dr. Lynn Kirkpatrick emphasized the importance of showcasing their transformative chemistry as they progress towards commercialization. The redesign was executed by London-based Flipside Health, specializing in digital healthcare solutions.
Ensysce Biosciences (NASDAQ:ENSC, OTC:ENSCW), a clinical-stage biotech firm, announced its participation in several upcoming conferences aimed at improving prescription drug safety. Key events include the PAINWeek Conference from September 6-9, 2022, where CEO Dr. Lynn Kirkpatrick will chair a symposium, and the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The meetings will provide opportunities for one-on-one discussions with company executives regarding their transformative technologies for pain management.
FAQ
What is the current stock price of Ensysce Biosciences (ENSC)?
What is the market cap of Ensysce Biosciences (ENSC)?
What is Ensysce Biosciences, Inc.?
What technologies does Ensysce use in its drug development?
What are the core products in Ensysce’s development pipeline?
What recent achievements have Ensysce made?
What is the significance of FDA Breakthrough Therapy designation?
How is Ensysce addressing the opioid epidemic?
What financial strategies support Ensysce’s operations?
What partnerships has Ensysce formed to advance its drug development?
What future projects is Ensysce Biosciences involved in?
Where can more information about Ensysce Biosciences be found?
